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To explore how well the safety net performs at eliminating differences in diagnosis and treatment of
insured and uninsured women with breast cancer, we compared insured and uninsured women treated
in a safety net setting.  Controlling for socioeconomic characteristics, uninsured women are more likely
to be diagnosed with advanced disease, requiring more extensive treatment relative to insured women,
and also experience delays in initiating and completing treatment.  The findings suggest that, despite
the safety net system, uninsured women with breast cancer are likely to require more costly treatment
and to have worse outcomes, relative to insured women with breast cancer.
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  The Institute of Medicine’s report, Insuring America’s Health: Principles and 
Recommendations, highlighted the sub-par health care of uninsured persons 
(approximately 43 million people) and called for universal health insurance (Institute of 
Medicine 2004).  Instead of universal coverage, the United States (U.S.) relies on a safety 
net system to treat uninsured patients, including patients with chronic, life threatening, 
and costly diseases such as breast cancer.  Breast cancer is the second leading cause of 
cancer death for women and the third leading cause of death in women overall (American 
Cancer Society 2006). 
   
In this study, we compare diagnosis and treatment between insured and uninsured 
women with breast cancer treated in a safety net setting, to explore how well the safety 
net system performs in eliminating differences in diagnosis and health care between 
insured and uninsured women.  Treatment patterns observed at a large safety net provider 
may offer the best evidence to study differences between insured and uninsured patients.  
Because the population of interest is the uninsured, there is not a single repository of 
claims data (e.g., Medicaid, Medicare, Anthem) that documents treatment history.  
Although our study is specific to a single health care facility, we are able to provide a 
detailed characterization, using administrative billing data, of the treatment of the 
uninsured.  While larger scale studies (for example, Ayanian et al., 1993) have confirmed 
that uninsured patients have worse survival than insured patients, because of the absence 
of detailed information on treatment the reasons for this disparity are unknown. 
Safety net providers are often associated with urban academic institutions that 
diagnose and treat a significant proportion of a community’s indigent population by 
offering diagnostic and treatment services at no or low cost, based on the patient’s assets 
and income.  In addition to safety net providers, there are also other options for 2 
subsidized health care for low-income uninsured women.  For example, the Centers for 
Disease Control National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) provides access to breast and cervical cancer screening services for 
underserved women in the U.S. (Centers for Disease Control 2006).
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Nonetheless, on average uninsured women with breast cancer are diagnosed at a 
later stage, and have poorer survival than insured women (Ayanian 1993).  Our research 
explores how effective the safety net system is at eliminating differences between insured 
and uninsured patients in the diagnosis and treatment of breast cancer.  Breast cancer 
represents a “best case scenario” for studying whether the safety net system can eliminate 
differences in diagnosis and treatment between insured and uninsured patients, given 
multiple options for free or low cost diagnosis and care, and given that patients are likely 
to be motivated to follow and complete recommended therapy.   
Conceptual Framework 
Differences in diagnosis, treatment, and survival between insured and uninsured 
women could be explained by a failure of safety net or other institutions to close the gap 
between these two groups, or by a lack of access to these institutions on the part of some 
women.  Alternatively, these differences could be attributable to variation in behavior 
related to health and health care — perhaps associated with factors such as 
socioeconomic status — which are correlated with but not caused by health insurance 
status.  Because these differences may have as much or more influence on health and 
health care behavior than does health insurance, failure to account for such differences 
likely results in overestimation of the deleterious effects of being uninsured (Currie and 
Thomas 1995; Doyle 2005).   
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We therefore structure our conceptual model to include individual and contextual 
differences that influence health care utilization.  A considerable body of research has 
demonstrated a relationship between breast cancer screening and/or stage at diagnosis 
and individual characteristics such as age, race, income, marital status, and education 
(Bradley et al. 2002; Anderson et al. 2007; Schootman et al. 2007; Taplin et al. 2004).  
These factors are also correlated with having health insurance.  A sparser but growing 
body of literature suggests that contextual factors (i.e., characteristics of the geographic 
location in which an individual resides) also are associated with and may influence health 
care utilization (Coughlin et al. 2007).  These factors include racial/ethnic composition 
(Benjamins et al. 2004) and education and income level (Engelman et al 2002) of the 
surrounding population as well as supply of health care providers within a geographic 
location (Davidson et al. 2005).     
We incorporate contextual factors in our model by using patients’ address 
information to identify their census tract of residence.  Census tracts are small 
subdivisions of counties established by the U.S. Census Bureau, usually with 2,500 to 
8,000 residents, and are designed to be homogeneous with respect to population 
characteristics, economic status, and living conditions (U.S. Census Bureau 2007).  The 
Public Health Disparities Geocoding Project demonstrated that poverty at the level of the 
census tract captured socioeconomic differences in health across a wide range of health 
outcomes, including outcomes related to cancer (Krieger et al. 2002).  We include in our 
models census tract characteristics that emerge from the literature as predictors of health 
care utilization, along with additional characteristics (e.g., proportion of families headed 
by single females, housing units without a motor vehicle) that may be correlated with 
socioeconomic vulnerability and poor access to health care.  In addition, we estimate 4 
models with fixed effects for each census tract, which capture all of these measurable 
factors defined at the census tract level, as well as any other unmeasured factors common 
to residents of the same tract.   
Study Data and Methods 
Context 
We evaluate the effect of health insurance on breast cancer diagnosis and 
treatment at a large urban safety net hospital system — Virginia Commonwealth 
University Health Care System’s (VCUHS) Massey Cancer Center (MCC).  MCC is an 
integral component of a healthcare system serving the cancer care needs of patients in the 
Greater Richmond Virginia Metropolitan Area and surrounding counties (a population of 
approximately 1.7 million people).  As a safety net provider, many uninsured patients are 
drawn to MCC.  When uninsured (or underinsured) patients make an appointment at 
VCUHS, their level of financial need is assessed.  Based on their income, VCUHS will 
offer care at low or no cost.  MCC is also a National Cancer Institute designated clinical 
cancer center, which attracts and treats patients regardless of health insurance status.  
VCUHS inpatient facilities are located in downtown Richmond, but it has two outpatient 
facilities that offer mammography services for screening and diagnosis and deliver 
chemotherapy; one is located downtown, and the other, in a suburban setting, caters to an 
insured population.  Uninsured patients are screened and treated in the downtown facility 
and are seen in the oncology fellows’ clinic for chemotherapy administration. 
Among women treated at VCUHS, we compare tumor size and stage of breast 
cancers at diagnosis — which are strong predictors of breast cancer survival (Smigal et 
al. 2006; Carter et al. 1989; Rosenberg et al. 2005; Elkin et al. 2005) — for women with 
and without insurance.  We also compare the time from diagnosis to surgery and from 5 
surgery to the start of adjuvant chemotherapy, the likelihood of starting and completing 
chemotherapy, and the time to complete chemotherapy regimens. 
Data and Study Sample 
Data were obtained from the hospital cancer registry, the VCUHS administrative 
billing system, and medical records.  The registry contains information on incident cancer 
cases, including: the American Joint Committee on Cancer (AJCC) Tumor Node 
Metastases (TNM) staging; date of diagnosis; and information about treatment including 
surgery, chemotherapy, and radiation.  The billing system contains information on: 
patient age, race, and marital status; address; inpatient, outpatient, and physician services; 
drugs administered (type, dose); dates of service; insurance source (at the time of first 
treatment for cancer at VCUHS); charges; International Classification of Diseases version 
9 codes; and Current Procedural Terminology codes.   
Records for all breast cancer patients identified through the cancer registry 
diagnosed between January 1, 1999 and March 31, 2006 were merged with the VCUHS 
administrative billing system.  Medical record numbers and dates of diagnosis were used 
to extract all billing claims from 3 months prior to 12 months following the diagnosis 
date.  For patients with more than one primary breast cancer, only the first cancer 
diagnosis was included.  A medical oncologist randomly selected and manually audited 
the medical records from 15% of the patients that received chemotherapy.  Insights from 
this audit guided our coding and interpretation of the billing records and ensured that all 
services and their dates were accurately recorded.  
VCUHS treats approximately 300 new breast cancer cases annually.  Patients 
treated at VCUHS are comparable, in terms of cancer stage at diagnosis, to patients 
treated at other Virginia teaching hospitals, Virginia community comprehensive cancer 6 
centers, and all Virginia hospitals combined.
2  However, VCUHS is the main safety 
provider in the region and, as such, it likely treats a disproportionate share of uninsured 
patients relative to other providers.  Although uninsured women are more likely to be 
diagnosed with advanced stage disease, their proportion of the total VCUHS cancer 
patient population is still somewhat small and alters only slightly the distribution of 
cancer stages diagnosed at VCUHS relative to other providers (for example, 59% of 
VCUHS breast cancer cases are diagnosed with in situ or local disease whereas other 
Virginia providers report that 60% of their cases are in situ or local stage).  All cancer 
patients seen at VCUHS are entered on its cancer registry.  Patients may receive a portion 
of their care elsewhere.  For example, VCUHS provides 53% and 75% of surgery and 
chemotherapy, respectively, to insured patients; the corresponding numbers for uninsured 
patients are 87% and 90%, respectively.  The registry includes all treatment information, 
regardless of location, up to and including the initiation of chemotherapy.
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We identified all women aged 21 to 64 diagnosed with a first primary breast 
tumor with an AJCC stage of 0, I, II, or III.  Patients with distant metastases, who were 
likely receiving palliative care without intent to cure, were excluded.  We chose 64 as the 
upper age limit because almost all women qualify for Medicare coverage at age 65.  
Because we were interested in the timing of surgery and outpatient chemotherapy, we 
excluded patients that died within 1 year of diagnosis (n=17), had no evidence of surgery 
(n=31), or had a bone marrow transplant (n=12).
4  We also excluded 60 women insured 
by Medicaid because we could not determine whether they were enrolled in Medicaid at 
the time of diagnosis or were uninsured at diagnosis with Medicaid enrollment made 
retroactive to the time of diagnosis.  Lastly, we excluded 50 women because we could not 7 
match their address to a census tract.  The remaining sample size was 1,334 women — 
1,121 with private or military insurance and 213 uninsured.   
Analytical Approach 
We first compared the stage of disease and tumor size (≥2 cm) in insured and 
uninsured patients using logistic regression.  AJCC disease stage was dichotomized into 
in situ (0) and local (I) versus regional (II, III).  Chemotherapy is recommended less often 
for women with in situ or local stage cancer whereas chemotherapy is routinely 
recommended to women with regional stage breast cancer.  In addition, because regional 
stage cancers are more advanced, the probability of cancer recurrence is higher for 
women with regional stage disease.  Tumors ≥2 cm indicate higher stage and — because 
women with a tumor this large likely presented with a palpable mass — the absence of 
mammography screening.  Cases missing tumor size (n=302) were excluded from this 
analysis.   
Second, we compared the number of days between diagnosis and surgery and 
between surgery and chemotherapy initiation and the likelihood of a delay of more than 
90 days from diagnosis to surgery between insured and uninsured patients.  These 
outcomes reflect the timeliness of care, which can influence its quality.  A meta-analysis 
of a variety of studies of this question finds that a delay of 12 or more weeks from 
symptom detection to treatment initiation is associated with a 15 percentage point lower 
survival rate at 20 years following diagnosis relative to women that had treatment within 
12 weeks of experiencing breast cancer symptoms (Richards et al. 1999).  The time from 
a suspicious mammogram to surgery would better reflect the time period between 
diagnosis and surgery, but these data are not available.  Therefore, our estimates are 
conservative relative to the actual time between diagnosis and surgery.  8 
From these analyses, we excluded patients with neoadjuvant chemotherapy 
(n=73), which introduces delays between diagnosis and surgery.  We conducted the 
analysis with and without patients that had identical surgery and diagnosis dates (n=351), 
because they likely received their initial biopsy and lumpectomy at the same time.  The 
distribution of the time between diagnosis and surgery was right skewed.  Therefore, we 
repeated the analysis using the natural log transformation of the dependent variable; the 
findings were qualitatively similar (results not shown).
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Third, we compared the likelihood of initiating and completing a chemotherapy 
regimen of doxorubicin plus cyclophosphamide (AC) or doxorubicin plus 
cyclophosphamide followed by paclitaxel (ACT), the two most common adjuvant 
regimens used to treat breast cancer patients (Levine and Whelan 2006).  For the patients 
that completed AC or ACT, we also compared the number of days from the start of 
chemotherapy to the completion of chemotherapy (AC, n=247; ACT, n=133).  A 
complete course of therapy was defined as 4 courses of AC or 8 courses of ACT.  In our 
analysis of chemotherapy completion, we limited the sample to patients that received all 
of their chemotherapy at VCUHS (n=526) to ensure that we had complete data.
6  Other 
protocols were prescribed during the study period, but their dosing schedules were 
irregular or they were administered as part of a clinical trial.  In a population-based study, 
Harlan et al. found that uninsured women were equally likely to receive guideline care as 
insured women (Harlan et al. 2005).  We would expect to find the same result for the 
safety net setting. 
For each outcome, we report estimates of three models.  Model 1 includes health 
insurance status, along with patient characteristics (e.g., race, age, marital status) to 
provide a baseline estimate of the differences between insured and uninsured women.  9 
Race is a prime socioeconomic variable that is associated with health insurance status
 
(Monheit and Vistnes 2000) and also with differences in diagnosis and treatment of 
breast cancer (Lantz et al. 2006).  In the models for days between diagnosis and surgery, 
surgery and chemotherapy initiation, and chemotherapy initiation and completion, Model 
1 also includes variables for cancer stage and tumor size and shortest distance to the 
VCUHS facility where chemotherapy could be administered.  Distance was included to 
reflect the possibility that uninsured patients may have to travel farther than insured 
patients to the safety net facility that will treat them.  In contrast, insured patients have 
the option of going to the closest facility.  For uninsured patients, the shortest distance 
was the number of miles between their residence and the downtown facility (Dalton 
clinic) where they have to be treated.  The shortest distance for insured patients was 
lesser of the distance between their residence and the Dalton clinic and between their 
residence and the suburban facility.  In the models for days between surgery and 
chemotherapy initiation and chemotherapy completion, a dichotomous variable for 
mastectomy is also added as a control, to account for longer recovery times associated 
with mastectomy.   
Model 2 estimates the insurance-related differential controlling for census tract 
characteristics including census tract median income, percent of women with some 
college and percent of women with a college degree or higher (relative to the percent of 
women with a high school or less education), median value of owner occupied housing, 
percent of families headed by unmarried women, percent of owner occupied housing, 
percent of blacks residing in the census tract, and percent of housing without a motor 
vehicle.   10 
Finally, Model 3 adds dichotomous variables for each census tract in which 
patients resided.  This approach controls for all tract-related differences in the 
environment and social context (e.g., transportation, housing) in which patients live, 
including differences in physical access to VCUHS.  Because the census tract controls 
should account for many socioeconomic differences between the insured and the 
uninsured, the differences that remain are much more likely due to differences in how 
well the safety net system reaches the uninsured and how it treats the uninsured once they 
have been diagnosed.  In Model 3, the effects of insurance status are identified from 
differences between insured and uninsured women within the same census tract.  Hence 
we drop observations in census tracts with only one patient, and, for the logistic models, 
additional observations for which census tracts perfectly predicted the outcome of 
interest.   
The differences we observe in chemotherapy-related outcomes may be 
attributable to differences in the two facilities at which patients receive care.  To address 
this potential source of bias, we repeat all chemotherapy related analyses on a sample 
restricted to those treated at the downtown facility.  As noted earlier, the insured patients 
can choose their facility, whereas all uninsured patients are treated at the downtown 
facility.  Thus, the only comparison we can do that controls for the facility at which 
treatment is received is the comparison for this subsample.   
Results  
Descriptive statistics by insurance status are reported in Table 1.  The insured and 
uninsured were of similar ages.  Uninsured women were more likely to be black and 
unmarried, and more likely to be diagnosed with advanced cancer stage and larger 
tumors.  As would be expected given cancer stage and tumor size, uninsured women were 11 
more likely to have a mastectomy and more likely to initiate chemotherapy.  Uninsured 
women had considerably longer times from diagnosis to surgery (24 or 19 days 
depending on whether we exclude or include patients diagnosed on the same day as 
surgery) and from surgery to chemotherapy initiation (21 days longer). A higher 
percentage of uninsured women experienced a delay of 90 or more days from diagnosis 
to surgery (23 versus 3 percent).  Once chemotherapy was initiated, insured women were 
more likely to complete chemotherapy.   
Among women that completed chemotherapy, uninsured women took longer to 
complete chemotherapy (approximately 4 and 32 days longer for AC and ACT, 
respectively).  AC is expected to be complete within 64 days and ACT should be 
completed within 148 days (Hershman et al. 2004).  Sixty-eight percent of insured 
women completed AC within 64 days and 69% of them completed ACT within 148 days.  
In contrast, less than half of uninsured women completed AC within 64 days and only 
35% completed ACT within 148 days.   
The lower panel of Table 1 reports census tract characteristics.  Along every 
dimension, census tracts where insured women resided were different from census tracts 
where uninsured women resided.  Insured women resided in census tracts with higher 
median income, high gross value of housing, and with greater shares of owner occupied 
housing and women with a college degree, but with fewer families headed by unmarried 
women, fewer homes without a motor vehicle, and shares of blacks relative to census 
tracts where uninsured women reside.  However, despite these differences, insured and 
uninsured women faced quite similar distances to the closest clinic where chemotherapy 
could be delivered.  The mean distance was 22 miles for insured women and 25 for 12 
uninsured women; the medians were 11 for insured women and 10 miles for uninsured 
women. 
Table 2 reports results from logistic regressions for regional AJCC stage and 
tumor size ≥2 cm.  In the Model 1 estimates, insured women were less likely to be 
diagnosed with regional stage disease (OR=0.72, p=0.06).  Adding the census tract 
characteristics in Model 2 does not alter the estimated differential, whereas the addition 
of individual census tract controls in Model 3 makes the estimated differential somewhat 
larger, with insured women two-thirds as likely to be diagnosed with late stage disease 
(OR=0.65, p=.05).  In column 2, the estimates for Models 1-3 all indicate that insured 
women were only about half as likely to be diagnosed with a tumor ≥2 cm than were 
uninsured women; the estimates are similar across all models (e.g., OR=0.53, p=0.02 in 
Model 3).  Consistent with the literature, the estimates indicate that African American 
women are more likely to be diagnosed with advanced stage and larger tumors relative to 
white women (Henson et al. 2003).  However, Table 2 shows that a large insurance-
related differential exists conditional on race, as well as other controls.   
Table 3 reports OLS estimates of models for days from diagnosis to surgery for 
all women and women that received their diagnosis on the same day as surgery.  The 
estimates in column 1 indicate that uninsured women receive their surgery 16 days later 
than insured women (p<0.01), regardless of model specification.  When we exclude 
women who were diagnosed and had surgery on the same day, in column 2, the estimated 
differences between insured and uninsured women widen slightly.  Finally, in estimations 
for the likelihood of having a delay of 90 days or more between diagnosis and surgery, 
insured women are much less likely to experience such a delay relative to uninsured 
women (OR=0.34, 95% CI= 0.17 to 0.69).  This estimate was robust across the 3 models, 13 
including Model 3 where the sample size dramatically decreased from 1261 to 360 due to 
the inclusion of census tract dummy variables.
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Table 4 reports results from logistic regressions for initiating chemotherapy, 
completing a regimen of AC or ACT, and experiencing a delay in the completion of 
either AC or ACT.  The estimates in column 1 indicate no significant differences between 
insured and uninsured women in the likelihood of initiating chemotherapy.  Likewise, the 
estimates in column 2 suggest no differences in the likelihood of chemotherapy 
completion.  However, in column 3, the estimates clearly indicate the insured women are 
less likely to have a delay in chemotherapy completion (OR=0.36, p<0.01, for Models 1 
and 2).  The estimated difference in the likelihood of delay is even larger when individual 
census tract controls are added in Model 3 (OR=0.14, p=0.01). 
Table 5 addresses the timeliness with which treatments are delivered and 
completed.  The Model 1 estimates indicate that insured women start chemotherapy 
approximately 18 days sooner than uninsured women (p<0.01).  Insured women also 
complete AC and ACT regimens 4 (p=0.01) and 24 (p<0.01) days faster, respectively, 
than uninsured women.  When individual census tracts are added, in Model 3, the 
coefficients for chemotherapy completion became statistically insignificant (and very 
small for ACT).  In general, though, the samples available for estimating the models for 
chemotherapy completion – especially for ACT – are very small, especially for uninsured 
women.  
Table 6 addresses the possibility of bias introduced by treatment at different 
facilities (the downtown Dalton clinic versus the suburban clinic).  For each outcome and 
model, however, the estimates are very similar to their full sample counterparts in Tables 
4 and 5, which suggests that differences we find between insured and uninsured women 14 
are not due to differences between the treatment sites at which the two groups of women 
tend to get treated.   
Possible Explanations for Differences 
To summarize, the combined results in Tables 2 through 6 establish that, in the 
safety net setting we study, insured women with breast cancer are diagnosed with smaller 
tumors and at earlier disease stages, and they receive surgery and initiate chemotherapy 
considerably faster than otherwise similar uninsured women; the evidence regarding 
whether insured women complete chemotherapy faster is more mixed, with some 
specifications pointing to significant differences.  On the other hand, race differences in 
treatment-related outcomes are quite small and generally insignificant, although African 
American women are more commonly diagnosed at a later stage and with larger tumors.  
Moreover, neither race differences nor other socioeconomic characteristics associated 
with census tract of residence account for the diagnosis and treatment time differences 
between insured and uninsured women.  A number of other factors may help to explain 
some of these differences, in some cases highlighting possible shortcomings of the safety 
net system.  
Stage and tumor size were much more advanced in uninsured women relative to 
insured women.  Larger tumors at diagnosis in uninsured patients may reflect poor access 
to care and cancer screening.  The number of tumors ≥2 cm has been steadily declining 
since 1980 — a decade that marked the beginning of the use of mammograms for breast 
cancer screening — but uninsured women are less likely to use mammography services 
relative to insured women (Coughlin et al. 2004).  It is possible that there are too few 
mammography providers available to uninsured women, making access to screening 
difficult or burdensome.  Alternatively, uninsured women may be unaware that low cost 15 
options for cancer screening exist and seek care only when they become aware of a 
palpable mass.  At least one study found that less than half of the uninsured who live near 
safety net providers are aware of their presence (Cunningham et al. 2007). 
It is unclear why the differences in timeliness of treatment persist in a safety net 
setting where treatment was provided without regard to insurance status.  Scheduling and 
keeping clinical appointments may be difficult for uninsured patients.  An analysis of the 
frequency of cancellations in the oncology fellows’ clinic, where uninsured patients are 
treated, found that uninsured patients were twice as likely to miss their appointments for 
treatment as were insured patients.  The reasons cited by patients for missing 
appointments included being unaware of the appointment, patient or family illnesses, or 
other emergencies and transportation problems (Youssef et al. 2006).  However, the 
interpretation of the results from this study is unclear because the analysis did not include 
other controls for patient characteristics that may be correlated with missed 
appointments; we conjecture that such behavior is likely to be related to factors such as 
socioeconomic status, access to transportation, etc., for which have been able to control 
in our analysis.   
The oncology clinic may also be overburdened with patients, making it difficult 
for physicians to see patients in a timely manner.  A report from the Kaiser Commission 
on Medicaid and the Uninsured (2005) argued that safety net spending has not kept pace 
with growth in the number of uninsured and the cost of treating them, and as a result 
predicted an increasing strain on the ability of safety net providers to meet the health care 
demands placed on them. 
Perhaps supportive care medications such as those that reduce nausea, which may 
improve tolerance to therapy, are too expensive for uninsured patients to purchase out-of-16 
pocket, and these patients therefore experience the toxic effects of chemotherapy at 
greater rates or severity than insured patients.  Uninsured women may also have more 
non-cancer related medical conditions that interfere with recovery from surgery and 
chemotherapy initiation and completion.  As suggestive evidence consistent with this 
hypothesis, we found that 22% of uninsured women were admitted to the hospital 
compared with 16% of insured women (p=0.09), and 26% had at least one emergency 
department (ED) visit compared with 10% of insured women (p<.01); these differences 
were largely associated medical conditions unrelated to cancer.  (However, we only 
detect admissions and ED visits at VCUHS, and insured women may be more likely to go 
elsewhere.)  A greater prevalence of other medical conditions among the uninsured 
interfering with cancer treatment would still point to shortcomings of the safety net 
system, although it would suggest that the differences based on insurance status are not 
solely attributable to differences in treatment after women are diagnosed with breast 
cancer.   
Implications of Inequality in Access and Care  
Safety net providers are supposed to act as substitutes for universal coverage in 
the United States.  In spite of proximity to a safety net provider that is a National Cancer 
Institute designated clinical cancer center, we find that uninsured women had more 
advanced cancer and larger tumors than otherwise similar women with health insurance.  
From a health outcomes perspective, the method of breast cancer detection 
(mammography versus clinical breast exam) alone has been shown to be an important 
prognostic factor, and larger tumor size at diagnosis has grave implications for patients’ 
long-term survival (Shen et al. 2005; Duffy et al. 2003; Michaelson et al. 2003; Berry et 
al. 2005; Cronin et al. 2006; Berry et al. 2006).  From the safety net system perspective, 17 
because uninsured women present with more advanced disease, they require more 
extensive and costly treatment.  In our sample, a higher proportion of uninsured women 
required mastectomy (37% versus 26%) and chemotherapy (62% versus 52%) relative to 
insured women.  They were also more likely to require the longer, more extensive 
regimen of ACT instead of AC (50% versus 41%, p=0.09).  Once they initiated therapy, 
there is evidence suggesting that these women had a more difficult time completing it in a 
timely fashion, although this evidence is not always statistically significant.  Together, 
these findings suggest considerable morbidity for the affected women at increased cost to 
the health care system. 
Uninsured women also experienced lengthy delays from diagnosis to surgery and 
from surgery to chemotherapy initiation and, once chemotherapy was initiated, delays in 
treatment completion relative to otherwise similar insured women.  However, in this 
safety net setting, insured and uninsured women were equally likely to initiate and 
complete chemotherapy.   Although short delays in treatment completion have not been 
shown to adversely affect survival or cancer recurrence, a delay of 3 or more months 
from symptom detection to treatment initiation is associated with compromised survival 
(Richards et al. 1999).  In our sample, uninsured women were more likely to experience a 
90-day delay between diagnosis and surgery relative to insured women. This estimate is 
conservative because it excludes time from symptom recognition or an abnormal 
mammogram to surgery. Our findings may partially explain why other studies have found 
survival disparities between insured and uninsured women, despite the safety net system. 
Our approach has some limitations.  First, it is confined to a single institution.  
This reduces generalizability, but also avoids heterogeneity across institutions.  Second, 
we do not have information on patient income, education, family, health behaviors, prior 18 
contact with the health care system, and work situations.  However, we did control for 
census tract of residence, which captures the social and geographic context in which 
patients live and is strongly related to income, employment, etc.  Third, patients that 
relied upon VCUHS for all of their treatment may differ (in comorbidity, severity, or 
recommended protocol) from patients that chose to get their chemotherapy elsewhere, 
especially for insured women who are likely to have more options.   
Implications for Policy 
An expansion of the safety net has been sought as a way to provide access to 
health care for uninsured persons (Hadley and Cunningham 2004; Office of Management 
and Budget 2002); in 2004, total federal safety net spending was $22.8 billion, which 
reflected a 15% increase over 2001 spending (Kaiser Commission on Medicaid and the 
Uninsured 2005).  Our study indicates that within a safety net provider — one that was 
equally likely to provide surgery and chemotherapy without regard to health insurance — 
uninsured breast cancer patients are more likely to be diagnosed with severe disease and 
to experience treatment delays that could ultimately affect their chances for survival and 
increase costs to the healthcare system.   
In other settings, uninsured patients have been shown to receive about half as 
much medical care as insured patients (Institute of Medicine 2004).
  Safety net providers, 
in all likelihood, reduce differences between the diagnosis and treatment of the insured 
and the uninsured.  Nonetheless, in our study of one safety net provider, important 
differences remain.  These differences are large and are robust to controlling for census 
tract of residence, race, and other demographic characteristics.  As a result, the diagnosis 
and treatment differences associated with health insurance status, within this safety net 
system, seem unlikely to be attributable to unmeasured socioeconomic differences 19 
between women with and without insurance.  Our evidence suggests, therefore, that 
safety net institutions — at least as they currently operate — are only a partial substitute 
for health insurance, and that a more comprehensive alternative for uninsured patients is 
needed.   
   
NOTES 
 
1.  The NBCCEDP is targeted to low-income women under age 65 that are uninsured 
or under-insured.  This program is administered by state health departments.  If 
cancer is detected under the auspices of this program, patients in 48 states are 
enrolled in Medicaid to cover their care. 
2.  Based on authors’ analysis of the Virginia data in the National Cancer Data Base.  
(http://www.facs.org/ncdbbenchmarks8.cfm, accessed February 2007). 
3.  The cancer registry records information on all incident cancer cases evaluated at 
VCUHS.   
4.  Patients that received a bone marrow transplant are generally hospitalized for 
extended periods of time.  Therefore, they would not be expected to start and 
complete chemotherapy in the same time period as patients receiving outpatient 
chemotherapy. 
5.  For the analysis including women with simultaneous diagnosis and surgery, for 
those whose diagnosis and surgery were on the same day we first reset day until 
surgery from 0 to 1 before taking logs. 
6.  The VCUHS cancer registry does not indicate the type of chemotherapy 
administered to patients or if patients completed a prescribed regimen.  The only 
source of this information is administrative billing data. 
7.  Since the frequency of delays of 90 days or more is so low for insured women 
(2.8%, as reported in Table 1), in the logistic model with census tract dummy 
variables, the number of tracts with perfect predictions for the dependent variable is 
very high.    
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Table 1.  Patient, tumor, and treatment characteristics of women by insurance type 











 N(%)  N(%)   
Race     <0.001 
  Non-black   866 (77.25)  81 (38.03)   
  Black  255 (22.75)  132 (61.97)   
Marital status      <0.001 
  Married  814 (69.01)  66 (30.99)   
  Unmarried  307 (27.39)  147 (69.01)   
Stage     0.03 
  0  246 (21.94)  36 (16.90)   
  I  425 (37.91)  68 (31.92)   
  II  352 (31.40)  85 (39.91)   
  III  98 (8.74)  24 (11.27)   
Tumor size      <0.001 
  <2 cm  550 (49.06)  73 (34.27)   
  2-5 cm  268 (23.91)  74 (34.74)   
  >5 cm  47 (4.19)  20 (9.39)   
 Size missing  256 (22.84)  46 (21.60)   
Mastectomy  296 (26.40)  79 (37.09)  0.001 
90 day delay between diagnosis and surgery
b  31 (2.88)  50 (23.47)   
Any chemotherapy  581 (51.83)  131 (61.50)  0.001 
Completed chemotherapy, AC or ACT (n=526)  369 (88.92)  90 (81.08)  0.03 
Completed AC within 64 days
b (n=247)  133 (68.03)  17 (43.59)  0.02 
Completed ACT within 148 days
b (n=133)  84 (68.85)  9 (34.62)  0.001 
  Mean (SD)  Mean (SD)   
Age   50.35 (7.62)  49.58 (9.05)  0.16 
Days from diagnosis to surgery (N=1261), all 
patients
 b  24.42 (27.46)  43.13 (48.98)  <0.001 
Days from diagnosis to surgery, excluding women 
with surgery and diagnosis on same day (N=910)
b  33.99 (26.91)  58.35 (48.56)  <0.001 
Days from surgery to chemotherapy initiation 
(N=474)
c  48.85 (25.51)  69.48 (47.32)  <0.001 
Days from 1
st chemotherapy to last chemotherapy
d      
  AC (n=247)  65.50 (6.15)  69.41 (8.14)  <0.001 
  ACT (n=133)  127.62 (27.40)  159.62 (36.39)  <0.001 
Shortest distance to facility  21.59 (27.55)  24.64 (29.85)  0.15 
Census tract characteristics      
Median income  $53,259 ($21,546)  $37,856 ($14,296)  <0.001 
Median gross value of owner occupied homes  $130,566 
($59,450) 
$92,578 ($34,561)  <0.001 
Share families headed by unmarried females   9.49 (7.49)  17.07 (12.21)  <0.001 
Share black race  24.53 (23.73)  48.03 (30.52)  <0.001 
Share total owner occupied housing   77.35 (17.38)  64.39 (21.63)  <0.001 
Share of housing without a vehicle  6.50 (7.10)  14.03 (14.40)  <0.001 
Share females with high school or less education  43.81 (17.29)  55.81 (14.09)  <0.001 
Share females with some college  28.36 (5.67)  27.09 (6.75)  <0.001 
Share females with college degree or higher  27.83 (16.15)  17.10 (11.07)  <0.001 
Notes: SD=standard deviation, AC=doxorubicin plus cyclophosphamide, ACT=doxorubicin plus 
cyclophosphamide followed by paclitaxel.   
aSignificance level is based on tests of equality of means for continuous variables, and is determined by the t-
test; for the categorical variables it is based on the test for statistical independence, and is determined by the 
Likelihood Ratio Chi-square test. 
bWomen who did not have neoadjuvant chemotherapy. 
cWomen who initiated AC or ACT chemotherapy, but did not have neoadjuvant therapy. 
dWomen who completed ACT or ACT, did not have neoadjuvant therapy, and did not have surgery after 
chemotherapy began.    
Table 2.  Likelihood of late stage cancer and tumors ≥2 cm, women with breast 









Tumor size ≥2 cm 
p-
value 
  Insured, N=1121 
Uninsured, N=213  
  Insured, N=865 
Uninsured, N=167 
 
  (1)    (2)   
Model 1: Controlling for patient characteristics  
Insured  0.72 (0.52 to 1.01)  0.06  0.51 (0.36 to 0.74)  <0.001 
Uninsured  1.0  (referent)  1.0  (referent)  
Black  1.39 (1.08 to 1.81)  0.01  1.52 (1.13 to 2.04)  0.01 
Non-Black  1.0  (referent)  1.0  (referent)  
Married  1.07 (0.83 to 1.38)  0.61  1.04 (0.78 to 1.39)  0.79 
Unmarried  1.0  (referent)  1.0  (referent)  
Age at diagnosis  0.97 (0.95 to 0.98)  <0.001  0.97 (0.95 to 0.98)  <0.001 
 Pseudo  R
2  =  0.02  Pseudo  R
2 = 0.04   
Model 2: Controlling for census tract characteristics added to Model 1
b  
Insured  0.71 (0.51 to 0.99)  0.04  0.53 (0.37 to 0.77)  0.001 
Uninsured  1.0  (referent)  1.0  (referent)  
Black  1.42 (1.05 to 1.93)  0.02  1.44 (1.00 to 2.06)  0.05 
Non-Black  1.0  (referent)  1.0  (referent)  
Married  1.07 (0.82 to 1.38)  0.62  1.04 (0.78 to 1.40)  0.77 
Unmarried  1.0  (referent)  1.0  (referent)  
Age at diagnosis  0.97 (0.95 to 0.98)  <0.001  0.97 (0.95 to 0.98)  <0.001 
Median income  0.89 (0.76 to 1.05)  0.17  0.95 (0.78 to 1.16)  0.63 
Share families headed by unmarried 
females 
1.01 (0.99 to 1.04)  0.21  1.02 (0.99 to 1.05)  0.21 
Share black race   1.00 (0.99 to 1.01)  0.50  0.99 (0.98 to 1.00)  0.18 
Share total owner occupied housing  1.01 (1.00 to 1.02)  0.17  1.01 (0.99 to 1.02)  0.24 
Share females with some college  1.00 (0.98 to 1.03)  0.72  0.99 (0.96 to 1.02)  0.46 
Share females with college degree 
or higher 
1.01 (1.00 to 1.02)  0.36  1.00 (0.98 to 1.02)  0.90 
Median gross value of owner 
occupied housing 
0.99 (0.94 to 1.04)  0.76  0.96 (0.90 to 1.03)  0.27 
Share of housing without a vehicle  0.99 (0.96 to 1.03)  0.21  0.99 (0.97 to 1.02))  0.59 
 Pseudo  R
2  =  0.03  Pseudo  R
2 = 0.05   
Model 3: Census tract dichotomous variables added to Model 1
c 
 Insured,  N=951 
Uninsured, N=168   
Insured, N=677 
Uninsured, N=118   
Insured  0.65 (0.42 to 1.00)  0.05  0.53 (0.31 to 0.89)  0.02 
Uninsured  1.0  (referent)  1.0  (referent)  
 Pseudo  R
2  =  0.10  Pseudo  R
2 = 0.11   
Notes: OR=odds ratio, CI=confidence interval, AJCC=American Joint Committee on Cancer.   
aCI’s are based on robust standard errors.   
bMedian values (income and gross value of owner housing) were divided by $10,000.  Shares range from 0 to 100. 
cControl variables in not listed for Model 3 are the same as in Model 1.  Coefficients for individual census tracts 
are not reported.  
Table 3.  Days until surgery and likelihood of a 90 day delay from diagnosis to surgery (OR and 95% CI), women 







patients)  p-value 
Days from diagnosis to 
surgery (excludes 
simultaneous diagnosis 
and surgery date)  p-value 
Delay of 90 or more 
days from diagnosis to 
surgery  p-value 
 
Insured, N=1077 
Uninsured, N=184   
Insured, N=774 




  (1)   (2)   (3)  
  Model 1: Controlling for patient characteristics   
Insured  -15.83 (4.11)  <0.001  -21.09 (4.83)  <0.001  0.34 (0.17 to 0.69)  0.003 
Uninsured   (referent)    (referent)   1.0  (referent)   
Black  3.69 (2.27)  0.10  7.37 (2.66)  0.01  2.04 (1.06 to 3.94)  0.03 
Non-Black   (referent)     (referent)   1.0  (referent)   
Married  -3.13 (2.03)  0.12  -2.01 (2.33)  0.39  0.73 (0.40 to 1.36)  0.33 
Unmarried (referent)      (referent)   1.0  (referent)   
Age at diagnosis  0.17 (0.11)  0.14  0.15 (0.13)  0.25  1.02 (0.98 to 1.06)  0.32 
Stage 0  (referent)    (referent)   1.0  (referent)   
Stage I  5.42 (3.19)  0.09  1.86 (3.77)  0.62  2.03 (0.69 to 5.95)  0.20 
Stage II  4.87 (3.55)  0.17  1.50 (4.21)  0.72  1.65 (0.57 to 4.81)  0.36 
Stage III  9.62 (6.41)  0.13  16.83 (8.19)  0.04  4.89 (1.51 to 15.79)  0.01 
Tumor size <2 cm  (referent)    (referent)   1.0  (referent)   
Tumor size 2-5 cm  1.72 (2.90)  0.55  -0.61 (3.43)  0.86  1.02 (0.40 to 2.56)  0.98 
Tumor size >5 cm  0.21 (7.21)  0.98  -0.96 (9.28)  0.92  1.89 (0.45 to 7.91)  0.38 
Tumor size missing  9.00 (3.51)  0.01  9.95 (4.82)  0.02  2.07 (0.83 to 5.14)  0.12 
 R
2=0.06   R
2=0.11   Pseudo  R
2 = 0.10   
Model 2: Controlling for census tract characteristics added to Model 1
a 
Insured  -15.96 (4.19)  <0.001  -20.87 (4.89)  <0.001  0.37 (0.18 to 0.75)  0.01 
Uninsured   (referent)    (referent)   1.0  (referent)   
 R
2=0.07   R
2=0.12   Pseudo  R
2 = 0.12   
Model 3: Census tract dichotomous variables added to Model 1
a,b 
  




Insured  -15.53 (5.20)  0.003  -18.62 (6.71)  0.01  0.39 (0.15 to 1.00)  0.05 
Uninsured   (referent)    (referent)   1.0  (referent)   
 R
2=0.34   R
2=0.40   Pseudo  R
2 = 0.27   
Notes:  Robust standard errors are shown in parentheses in columns 1 and 2.  OR=odds ratio, CI=confidence interval. CI’s in column 3 are based 
on robust standard errors.  
aModels 2 and 3 control for race (black or non-black), age at diagnosis (continuous), marital status (married or unmarried), AJCC cancer stage (0, 
I, II, or III), and tumor size (<2 cm, 2 to 5 cm, or ≥5 cm).  Census tract characteristics included in Model 2 are the same as those reported for 
Model 2 in Table 2.  Odds ratios for these variables are not reported. 
bCoefficients for individual census tracts are not reported.  
Table 4.  Likelihood of initiating and completing chemotherapy, women with breast cancer age 21 to 64 years, 
1999-2006 (OR and 95% CI) 
Independent variables 
Initiated 














Uninsured, N=213   
Insured, N=415 




  (1)    (2)    (3)   
Model 1: Controlling for patient characteristics 
Insured  0.73 (0.45 to 1.78)  0.20  1.84 (0.92 to 3.70)  0.09  0.36 (0.20 to 0.68)  0.001 
Uninsured 1.0  (referent)    1.0  (referent)  1.0  (referent)   
Black  0.83 (0.57 to 1.19)  0.31  1.30 (0.70 to 2.41)  0.41  0.84 (0.50 to 1.42)  0.52 
Non-Black 1.0  (referent)    1.0  (referent)  1.0  (referent)   
Married  1.03 (0.73 to 1.45)  0.88  1.13 (0.62 to 2.07)  0.69  0.85 (0.53 to 1.36)  0.49 
Unmarried 1.0  (referent)    1.0  (referent)  1.0  (referent)   
Age at diagnosis  0.95 (0.93 to 0.97)  <0.001  0.98 (0.95 to 1.02)  0.34  0.98 (0.96 to 1.01)  0.23 
Mastectomy  1.34 (0.93 to 1.91)  0.17  1.10 (0.64 to 1.89)  0.73  0.88 (0.56 to 1.38)  0.57 
Late stage  20.78 (13.56 to 31.84)  <0.001  0.38 (0.18 to 0.83)  0.02  0.49 (0.29 to 0.85)  0.01 
Tumor size <2 cm  1.0 (referent)    1.0 (referent)    1.0 (referent)   
Tumor size 2-5 cm  0.79 (0.47 to 1.34)  0.38  2.00 (1.00 to 3.99)  0.05  1.30 (0.75 to 2.27)  0.35 
Tumor size >5 cm  2.80 (0.72 to 10.90)  0.14  0.33 (0.14 to 0.76)  0.01  4.05 (1.36 to 12.06)  0.01 
Tumor size missing  0.13 (0.09 to 0.20)  <0.001  0.97 (0.37 to 2.55)  0.94  0.71 (0.28 to 1.82)  0.48 
Shortest distance to facility   0.995 (0.988 to 1.00)  0.06  1.00 (0.99 to 1.01)  0.77  1.00 (0.28 to 1.82)  0.49 
 Pseudo  R
2 = 0.39    Pseudo R
2 = 0.18    Pseudo R
2 = 0.06   
Model 2: Census tract characteristics added to Model 1
a 
Insured  0.70 (0.42 to 1.13)  0.14  1.77 (0.86 to 3.65)  0.12  0.36 (0.18 to 0.70)  0.002 
Uninsured 1.0  (referent)   1.0  (referent)       
Shortest distance to facility  1.00 (0.99 to 1.00)  0.20  1.00 (0.99 to 1.01)  0.59  1.00 (1.00 to 1.01)  0.35 
  Pseudo R
2 = 0.39    Pseudo R
2 = 0.10    Pseudo R
2 = 0.08   
Model 3: Census tract dichotomous variables added to Model 1
a,b 
 Insured,  N=933 
Uninsured, N=169   
Insured, N=131 




Insured  0.54 (0.26 to 1.14)  0.11  2.51 (0.74 to 8.52)  0.14  0.14 (0.04 to 0.55)  0.01 
Uninsured 1.0  (referent)    1.0  (referent)  1.0  (referent)   
Shortest distance to facility  0.99 (0.98 to 1.00)  0.07  1.04 (0.97 to 1.11)  0.30  1.05 (1.00 to 1.09)  0.03 
 Pseudo  R
2 = 0.50    Pseudo R
2 = 0.29    Pseudo R
2 = 0.21   
Notes:  OR=odds ratio, CI=confidence interval.  CI’s are based on robust standard errors.  AC= doxorubicin plus cyclophosphamide, ACT= 
doxorubicin plus cyclophosphamide followed by paclitaxel.   
aModels 2 and 3 control for race (black or non-black), age at diagnosis (continuous), marital status (married or unmarried), late stage, and tumor 
size (<2 cm, 2 to 5 cm, or ≥5 cm).  Census tract characteristics included in Model 2 are the same as those reported for Model 2 in Table 2.  Odds 
ratios for these variables are not reported. 
bCoefficients for individual census tracts are not reported.  
  










completion, AC  p-value 
Days from 
chemotherapy initiation 







Uninsured, N=87   
Insured, N=210 




  (1)    (2)    (3)   
Model 1: Controlling for patient characteristics 
Insured  -17.90 (5.79)  0.002  -4.29 (1.68)  0.01  -23.57 (7.29)  0.002 
Uninsured (referent)    (referent)   (referent)   
Black  10.41 (3.78)  0.01  -0.99 (0.96)  0.31  2.80 (6.14)  0.65 
Non-Black (referent)    (referent)   (referent)   
Married  0.17 (3.51)  0.96  0.55 (0.97)  0.57  -9.41 (6.51)  0.15 
Unmarried (referent)    (referent)   (referent)     
Age at diagnosis  0.21 (0.18)  0.25  -0.01 (0.05)  0.98  -0.08 (0.31)  0.80 
Mastectomy  3.31 (3.03)  0.28  -0.93 (0.77)  0.23  -3.13 (5.13)  0.54 
Late stage  -3.94 (3.38)  0.25  -2.89 (0.84)  0.001  -23.00 (13.86)  0.10 
Tumor size <2 cm  (referent)   (referent)    (referent)   
Tumor size 2-5 cm  -1.62 (3.20)  0.61  1.19 (0.84)  0.16  -1.94 (5.75)  0.74 
Tumor size >5 cm  -0.26 (9.13)  0.98  7.48 (11.50)  0.52  15.93 (13.85)  0.25 
Tumor size missing  5.26 (5.76)  0.36  -0.18 (1.62)  0.91  17.58 (13.75)  0.20 
Shortest distance to facility  0.02 (0.04)  0.74  0.01 (0.02)  0.71  0.02 (0.05)  0.74 
 R
2 = 0.10    R
2 = 0.10    R
2 = 0.23   
Model 2: Census tract characteristics added to Model 1
a 
Insured  -17.52 (5.73)  0.002  -4.11 (1.78)  0.02  -16.17 (7.31)  0.03 
Uninsured   (referent)   (referent)       
Shortest distance to facility  0.01 (0.5)  0.79  0.01 (0.02)  0.76  0.01 (0.06)  0.90 
  R
2 = 0.11    R
2 = 0.15    R
2 = 0.33   
Model 3: Census tract dichotomous variables added to Model 1
a,b 
Insured  -23.09 (10.31)  0.03  -4.85 (3.56)  0.18  0.47 (24.09)  0.98 
Uninsured (referent)    (referent)   (referent)   
Shortest distance to facility  -0.05 (0.11)  0.61  0.16 (0.15)  0.30  -0.08 (0.14)  0.61 
 R
2 = 0.53    R
2 = 0.81    R
2 = 0.84   
Notes:  AC= doxorubicin plus cyclophosphamide, ACT= doxorubicin plus cyclophosphamide followed by paclitaxel.  Robust standard errors shown in 
parentheses.  
aModels 2 and 3 control for race (black or non-black), age at diagnosis (continuous), marital status (married or unmarried), late stage, and tumor size (<2 
cm, 2 to 5 cm, or ≥5 cm).  Census tract characteristics included in Model 2 are the same as those reported for Model 2 in Table 2.  Odds ratios for these 
variables are not reported. 
bCoefficients for individual census tracts are not reported.  
  
Table 6.  Likelihood of completing chemotherapy (OR and 95% CI), days until chemotherapy initiation, and days until chemotherapy completion, 








































Uninsured, N=107   
Insured, N=159 
Uninsured, N=65   
Insured, N=187 
Uninsured, N=85   
Insured, N=101 
Uninsured, N=35   
Insured, N=46 
Uninsured, N=26   
  (1)   (2)   (3)    (4)    (5)   
Model 1: Controlling for patient characteristics 
Insured  1.96 (0.78 to 3.42)  0.20  0.35 (0.18 to 0.69)  0.002  -19.25 (6.17)  0.002  -5.18 (1.90)  0.01  -14.65 (7.21)  0.05 
Uninsured  1.0 (referent)    1.0 (referent)   (referent)  (referent)    (referent)   
Black  1.55 (0.79 to 306)  0.21  0.89 (0.46 to 1.72)  0.73  12.55 (4.93)  0.01  -0.93 (1.44)  0.52  -1.05 (7.19)  0.88 
Non-Black  1.0 (referent)    1.0 (referent)   (referent)  (referent)    (referent)   
Married  0.93 (0.44 to 1.96)  0.69  0.86 (0.45 to 1.64)  0.64  6.21 (5.47)  0.26  0.12 (1.68)  0.94  -10.23 (8.04)  0.21 
Unmarried  1.0 (referent)    1.0 (referent)   (referent)  (referent)    (referent)    
Age at diagnosis  0.98 (0.94 to 1.02)  0.25  1.00 (0.96 to 1.04)  0.87  0.31 (0.25)  0.21  -0.01 (0.06)  0.94  0.24 (0.37)  0.52 
Mastectomy  0.83 (0.43 to 1.60)  0.59  0.96 (0.52 to 1.78)  0.89  4.73 (4.81)  0.33  -1.18 (1.22)  0.34  -6.73 (6.61)  0.31 
Late stage  0.33 (0.12 to 0.88)  0.02  0.39 (0.18 to 0.84)  0.02  -2.58 (5.12)  0.62  -4.34 (1.11)  <0.001  -32.74 (14.46)  0.03 
Tumor size <2 cm  1.0 (referent)    1.0 (referent)  (referent)  (referent)   (referent)  
Tumor size 2-5 cm  2.14 (0.89 to 5.12)  0.09  2.37 (1.08 to 5.18)  0.03  -5.36 (5.13)  0.30  1.97 (1.22)  0.11  -6.12 (8.32)  0.47 
Tumor size >5 cm  0.37 (0.13 to 1.07)  0.07  8.11 (1.92 to 34.31)  0.004  -12.51 (12.34)  0.31  -3.92 (6.37)  0.54  25.83 (17.76)  0.15 
Tumor size missing  1.18 (0.34 to 4.10)  0.79  1.11 (0.34 to 3.58)  0.86  4.07 (8.46)  0.63  1.49 (3.02)  0.62  3.96 (10.93)  0.72 
Miles to Dalton  1.00 (0.99 to 1.01)  0.43  1.00 (0.99 to 1.01)  0.57  -0.02 (0.07)  0.75  0.01 (0.02)  0.41  -0.06 (0.06)  0.31 
 Pseudo  R
2 = 0.10    Pseudo R
2 = 0.09    R
2 = 0.13    R
2 = 0.15    R
2 = 0.28   
Model 2: Census tract characteristics added to Model 1
b 
Insured  1.68 (0.76 to 3.71)  0.20  0.35 (0.17 to 0.73)  0.01  -17.52 (5.73)  0.002  -5.47 (1.97)  0.01  -8.65 (7.47)  0.25 
Uninsured 1.0  (referent)       (referent)    (referent)       
  Pseudo R
2 = 0.14    Pseudo R
2 = 0.11    R
2 = 0.11    R
2 = 0.19    R
2 = 0.45   
Notes:  OR=odds ratio, CI=confidence interval.  CI’s in columns 1 and 2 are based on robust standard errors.  Robust standard errors are shown in parentheses in columns 3-5.  
AC= doxorubicin plus cyclophosphamide, ACT= doxorubicin plus cyclophosphamide followed by paclitaxel.   
aThe specification with census tract dummy variables (Model 3 in Tables 2-5) is not estimated for the subsample treated at the downtown facility only due to limitations on the 
sample sizes. 
 
bModel 2 also controls for race (black or non-black), age at diagnosis (continuous), marital status (married or unmarried), AJCC cancer stage (0, I, II, or III), tumor size (<2 cm, 2 
to 5 cm, or ≥5 cm), and miles to Dalton, as well as the census tract characteristics reported for Model 2 in Table 2.  Coefficients for these variables are not reported.   
 
 